Anti-inflammatory treatment of acute and chronic pneumonia

Seminars in Respiratory Infections

Volumn 16, Issue 1, 2001, Pages 76-84

  Skerrett, Shawn J ^a   Park, David R ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETAMETHASONE; CORTICOSTEROID; HYDROCORTISONE; IBUPROFEN; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PREDNISOLONE;

ACUTE DISEASE; ADJUVANT THERAPY; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; CHRONIC DISEASE; DRUG EFFECT; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; PNEUMONIA; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS;

EID: 0035069441     PISSN: 08820546     EISSN: None     Source Type: Journal    
DOI: 10.1053/srin.2001.22731     Document Type: Review

References (77)

1. Corticosteroid-mediated immunoregulation in man
2. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids
3. Immunosuppression by glucocorticoids: Inhibition of NF-kappa B activity through induction of I kappa B synthesis
4. Guidelines for the use of systemic glucocorticoids in the management of selected infections. Working group on steroid use, antimicrobial agents committee, Infectious Disease Society of America
5. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome
6. Corticosteroids as adjunctive therapy in treatment of Pneumocystis carinii pneumonia in patients with acquired immune deficiency syndrome
7. Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immune deficiency syndrome
8. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome
9. Consensus statement on the use of corticosteroids as adjunctive therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome
10. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia
11. Septic shock from Mycobacterium tuberculosis after therapy for Pneumocystis carinii
12. Adrenocorticosteroids in the treatment of tuberculosis
13. Prednisolone in treatment of pulmonary tuberculosis: A controlled trial
14. Preliminary observations from a controlled trial of prednisolone in the treatment of pulmonary tuberculosis
15. Prednisolone in the treatment of acute extensive tuberculosis in West Africans
16. Corticotropin in the treatment of tuberculosis
17. A trial of corticotrophin and prednisone with chemotherapy in pulmonary tuberculosis
18. A randomized study of the effects of corticosteroid therapy on healing of pulmonary tuberculosis as judged by clinical, roentgenographic, and physiologic measurements
19. The role of adrenocorticotrophic and adrenocorticosteroid hormones in the treatment of tuberculosis
20. Corticosteroids in pulmonary tuberculosis. I. Over-all results in Madison-Minneapolis Veterans Administration hospitals steroid study
21. Tuberculosis, corticosteroid therapy, and pulmonary function
22. Study of chemotherapy regimens of 5 and 7 months' duration and the role of corticosteroids in the treatment of sputum-positive patients with pulmonary tuberculosis in South India
23. Adjunctive corticosteroid therapy for tuberculosis: A critical reappraisal of the literature
24. Corticosteroids in the treatment of tuberculous pleurisy. A double-blind, placebo-controlled, randomized study
25. Corticosteroids in the treatment of tuberculous pleurisy. A double-blind, placebo-controlled, randomized study
26. Effects of adrenocorticotropic hormone in pneumonia: Clinical bacteriological and serological studies
27. The effect of hydrocortisone upon the course of pneumococcal pneumonia treated with penicillin
28. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. A randomized controlled study
29. Corticosteroids in life-threatening varicella pneumonia
30. The effectiveness of hydrocortisone in the management of severe infections
31. Effectiveness of betamethasone in management of severe infections. A double-blind study
32. Steroids in the treatment of clinical septic shock
33. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study
34. Stress doses of hydrocortisone reverse hyperdynamic septic shock: A prospective, randomized, double-blind, single-center study
35. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock
36. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis
37. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock
38. Reversal of late-phase septic shock with supraphysiologic doses of hydrocortisone
39. The American-European consensus conference on ARDS, part 2
40. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome. A randomized controlled trial
41. Bronchiolitis obliterans organizing pneumonia
42. Cryptogenic organizing pneumonitis: Bronchiolitis obliterans organizing pneumonia
43. Bronchiolitis obliterans caused by Legionella pneumophila
44. Fulminant Mycoplasma pneumoniae pneumonia
45. Bronchiolitis obliterans organizing pneumonia associated with acute Mycoplasma pneumoniae infection
46. Bronchiolitis obliterans organizing pneumonia associated with chlamydial infection
47. Effect of indomethacin on arterial oxygenation in critically ill patients with severe bacterial pneumonia
48. Effect of acetylsalicylic acid on pulmonary gas exchange in patients with severe pneumonia: A pilot study
49. Ibuprofen modifies the inflammatory response of the murine lung to Pseudomonas aeruginosa
50. Piroxicam treatment protects mice from lethal pulmonary challenge with Pseudomonas aeruginosa
51. Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Implications for antiinflammatory therapy in cystic fibrosis
52. Aspirin impairs antibacterial mechanisms in experimental pneumococcal pneumonia
53. The effects of ibuprofen on the physiology and survival of patients with sepsis
54. Effect of high-dose ibuprofen in patients with cystic fibrosis
55. The role of cytokines in bacterial pneumonia: An inflammatory balancing act
56. Adenovirus-mediated blockade of tumor necrosis factor in mice protects against endotoxic shock yet impairs pulmonary host defense
57. Passive immunization against tumor necrosis factor-alpha impairs host defense during pneumococcal pneumonia in mice
58. Role of tumor necrosis factor alpha in pathogenesis of pneumococcal pneumonia in mice
59. Tumor necrosis factor mediates lung antibacterial host defense in murine Klebsiella pneumonia
60. Antibody-mediated depletion of tumor necrosis factor-α impairs pulmonary host defenses to Legionella pneumophila
61. Tumor necrosis factor-α is required in the protective immune response against Mycobacterium tuberculosis in mice
62. Exacerbation of murine Pneumocystis carinii infection by adenoviral-mediated gene transfer of a TNF inhibitor
63. Afferent phase production of TNF-α is required for the development of protective T cell immunity to Cryptococcus neoformans
64. Blockade of endogenous TNF-alpha exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms
65. Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment
66. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock: A randomized controlled multicenter trial
67. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock
68. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein
69. Treating patients with severe sepsis
70. Interleukin-10: Potential benefits and possible risks in clinical infectious diseases
71. IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense
72. IL-10 improves lung injury and survival in Pseudomonas aeruginosa pneumonia
73. IL-10 attenuates excessive inflammation in chronic Pseudomonas infection in mice
74. Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia
75. Interleukin-10 impairs host defense in murine pneumococcal pneumonia
76. Anti-inflammatory cytokines
77. Trial of corticotrophin and prednisone with chemotherapy in pulmonary tuberculosis: A two-year radiographic follow-up